World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
41472
World Ranking
11570
National Ranking
5939

Overview

Kim Margolin is affiliated with the City Of Hope National Medical Center in the United States. Their research primarily focuses on medicine, with a significant emphasis on oncology. Within this field, their work extensively covers oncology, immunology, pulmonary and respiratory medicine, molecular biology, and genetics.

The main topics of Margolin's research center on cancer immunotherapy and biomarkers, immunotherapy and immune responses, CAR-T cell therapy research, as well as brain metastases and treatment. Additional subject areas include cutaneous melanoma detection and management, melanoma and MAPK pathways, and lung cancer research studies.

Margolin has contributed to several recent publications, including:

  • Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma, 2023, New England Journal of Medicine
  • A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer, 2020, Cell
  • NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021, 2021, Journal of the National Comprehensive Cancer Network
  • Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial, 2023, Nature Medicine
  • Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204), 2021, Neuro-Oncology

Margolin frequently publishes in venues such as Annals of Oncology, Regular and Young Investigator Award Abstracts, Cancer Research, Journal for ImmunoTherapy of Cancer, and Cancers.

Collaborations are a notable aspect of Margolin's research career. Frequent coauthors include Michael B. Atkins, Antoni Ribas, Geoffrey T. Gibney, Hussein A. Tawbi, and Adil Daud.

Best Publications

  • High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

    Michael B. Atkins;Michael T. Lotze;Janice P. Dutcher;Richard I. Fisher

  • Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Dirk Schadendorf;F. Stephen Hodi;Caroline Robert;Jeffrey S. Weber

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Brian I. Rini;Brian I. Rini;Ronald M. Bukowski;Brendan D. Curti

  • Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

    M. S. Gordon;K. Margolin;M. Talpaz;G. W. Sledge

  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

    Paul T. Nghiem;Shailender Bhatia;Evan J. Lipson;Ragini R. Kudchadkar

  • Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

    Hussein A. Tawbi;Peter A. Forsyth;Alain Algazi;Omid Hamid

  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Bruce G. Redman

  • Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial

    Kim Margolin;Marc S Ernstoff;Omid Hamid;Donald Lawrence

  • Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

    David F. McDermott;Meredith M. Regan;Joseph I. Clark;Lawrence E. Flaherty

  • Response assessment criteria for brain metastases: proposal from the RANO group

    Nancy U Lin;Eudocia Q Lee;Hidefumi Aoyama;Igor J Barani

  • Cytokines in cancer immunotherapy

    Sylvia Lee;Kim Margolin

  • A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

    Patrick A. Ott;Siwen Hu-Lieskovan;Bartosz Chmielowski;Ramaswamy Govindan

  • NCCN clinical practice guidelines in oncology: kidney cancer.

    Robert J Motzer;Neeraj Agarwal;Clair Beard;Graeme B Bolger

  • Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data

    K. Margolin;M. S. Gordon;E. Holmgren;J. Gaudreault

  • Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

    Brian I. Rini;M. Dror Michaelson;Jonathan E. Rosenberg;Ronald M. Bukowski

  • Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

    K A Margolin;A A Rayner;M J Hawkins;M B Atkins

  • Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells: A Phase II Clinical Trial

    Fisher Ri;Coltman Ca;Doroshow Jh;Rayner Aa

  • Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

    Robert J. Motzer;Craig J. Nichols;Kim A. Margolin;Jennifer Bacik

  • Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial

    Joseph I. Clark;Michael B. Atkins;Walter J. Urba;Steven Creech

Frequent Co-Authors

James H. Doroshow
James H. Doroshow National Institutes of Health
George Somlo
George Somlo City Of Hope National Medical Center
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Michael B. Atkins
Michael B. Atkins Georgetown University
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Marc S. Ernstoff
Marc S. Ernstoff Roswell Park Cancer Institute
Stephen J. Forman
Stephen J. Forman City Of Hope National Medical Center
F. Stephen Hodi
F. Stephen Hodi Harvard University
John M. Kirkwood
John M. Kirkwood University of Pittsburgh
Ahmad A. Tarhini
Ahmad A. Tarhini Cleveland Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As interest in medical careers grows, many students consider alternative online degrees and certifications related to the field. Pursuing an online degree can make education more affordable and flexible, especially for those balancing work and family commitments.

For those interested in advanced practice, there are cheapest dnp programs available online, which prepare graduate nurses for leadership roles. Pharmaceutics is another popular option—students can now study through online pharmacist programs to become licensed pharmacists without having to relocate.

If you are interested in the business or technology side of healthcare, a bachelor of health information management online equips you with skills in data management and digital health records. Alternatively, those seeking a quicker entry point to healthcare can consider medical billing and coding online—a pathway that offers fast-track certifications and strong job demand.

These online programs provide diverse career paths beyond traditional medical school, opening up opportunities in specialized and rapidly growing fields within the US healthcare system.

Best Scientists Citing Kim Margolin

Trending Scientists